SkinBioTherapeutics (LON:SBTX) Trading 14.1% Higher – Should You Buy?

SkinBioTherapeutics plc (LON:SBTX) was up 14.1% during trading on Monday . The stock traded as high as GBX 11 and last traded at GBX 10.84. 424,315 shares were traded during mid-day trading, a decline of 87% from the average session volume of 3,278,070 shares. The stock had previously closed at GBX 9.50.

SkinBioTherapeutics Trading Up 14.1%

The stock has a market cap of £28.08 million, a price-to-earnings ratio of -67.72 and a beta of 0.11. The firm’s 50 day moving average is GBX 9.93 and its two-hundred day moving average is GBX 11.75. The company has a quick ratio of 10.01, a current ratio of 6.14 and a debt-to-equity ratio of 11.77.

SkinBioTherapeutics (LON:SBTX) last issued its earnings results on Monday, June 8th. The company reported GBX (0.31) EPS for the quarter. The company had revenue of GBX 217 million during the quarter. SkinBioTherapeutics had a negative net margin of 8.73% and a negative return on equity of 5.25%.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.